ArticlePLoS neglected tropical diseases2012
IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection.
Article in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Rapid phagosome formation drives parasite control in subclinicalFrontiers in immunology · 2026Article
- Cutaneous leishmaniasis in Afghanistan.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Review
- Cytokine Production in Response to Soluble Leishmania Aethiopica Antigen by Whole Blood Cells from Patients with Different Clinical Presentations of Cutaneous Leishmaniasis.The American journal of tropical medicine and hygiene · 2025Article
- Contrasting Phenotypes of Neutrophils During Asymptomatic Versus Symptomatic Leishmania braziliensis Infection.The Journal of infectious diseases · 2024Article
- ThePathogens (Basel, Switzerland) · 2024Article
- Clinical and parasitological features of Leishmania infection among gold miners in the Oiapoque basin, an international Brazil-French Guiana border.PLoS neglected tropical diseases · 2024Article
- Viable Leishmania parasites in the absence of an in vitro IFN-γ response in asymptomatic carriers.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Article
- A Prospective cohort study of zoonotic cutaneous leishmaniasis in tunisia: Clinical and Immunological features and immune correlates of protection.PLoS neglected tropical diseases · 2023Article
- Article
- Protection and Pathology inPathogens (Basel, Switzerland) · 2022Review
- Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.The Journal of infectious diseases · 2021Article
- Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- The F1F3 Recombinant Chimera ofFrontiers in immunology · 2019Article
- Cutaneous Manifestations of Human and Murine Leishmaniasis.International journal of molecular sciences · 2017Review
- Characterization of the Histopathologic Features in Patients in the Early and Late Phases of Cutaneous Leishmaniasis.The American journal of tropical medicine and hygiene · 2017Article
- Gene Expression Profile of High IFN-γ Producers Stimulated with Leishmania braziliensis Identifies Genes Associated with Cutaneous Leishmaniasis.PLoS neglected tropical diseases · 2016Article
- Immunity to Lutzomyia whitmani Saliva Protects against Experimental Leishmania braziliensis Infection.PLoS neglected tropical diseases · 2016Article
- Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.The Journal of infectious diseases · 2016Article
- Protein biomarkers discriminate Leishmania major-infected and non-infected individuals in areas endemic for cutaneous leishmaniasis.BMC infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundCutaneous leishmaniasis due to L. braziliensis (CL) is characterized by a positive delayed type hypersensitivity test (DTH) leishmania skin test (LST) and high IFN-γ production to soluble leishmania antigen (SLA). The LST is used for diagnosis of CL and for identification of individuals exposed to leishmania infection but without disease. The main aim of the present study was to identify markers of exposure to L. braziliensis infection. METHODOLGY/PRINCIPAL
findingsThis cohort study enrolled 308 household contacts (HC) of 76 CL index cases. HC had no active or past history of leishmaniasis. For the present cross-sectional study cytokines and chemokines were determined in supernatants of whole blood culture stimulated with SLA. Of the 308 HC, 36 (11.7%) had a positive LST but in these IFN-γ was only detected in 22 (61.1%). Moreover of the 40 HC with evidence of IFN-γ production only 22 (55%) had a positive LST. A total of 54 (17.5%) of 308 HC had specific immune response to SLA. Only a moderate agreement (Kappa = 0.52; 95% CI: 0.36-0.66) was found between LST and IFN-γ production. Moreover while enhancement of CXCL10 in cultures stimulated with SLA was observed in HC with DTH+ and IFN-γ+ and in patients with IFN-γ(+) and DTH(-), no enhancement of this chemokine was observed in supernatants of cells of HC with DTH(+) and IFN-γ(-). CONCLUSIONS/SIGNIFICANCE: This study shows that in addition of LST, the evaluation of antigen specific IFN-γ production should be performed to determine evidence of exposure to leishmania infection. Moreover it suggests that in some HC production of IFN-γ and CXCL10 are performed by cells not involved with DTH reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.